Date Posted: February 21, 2012
Date Posted: 21st February, 2012 Summary: At this year’s ASCPT meeting, to be held at the Gaylord National Hotel & Convention Center, National Harbor, Maryland from 12 – 17th March, Xceleron’s CSO, Dr Graham Lappin, will be giving a presentation entitled: “Analytical Technologies for Metabolite Identification and Quantitation” The talk will be given as partContinue Reading
Date Posted: February 21, 2012
Date Posted: 21st February, 2012 Summary: During the ASCPT meeting to be held at the Gaylord National Hotel & Convention Center National Harbor, Maryland, this year, Xceleron will be opening the doors to it’s purpose built facility in Germantown and arranging transport from the Gaylord National Conference Center to and from the site in Germantown.Continue Reading
Date Posted: February 6, 2012
Date Posted: 6th February 2012 Summary: XCELERON, a leader in accelerating drug development using ultra-sensitive bioanalytical analyses, today announced that existing investors Albion Ventures and Solon Ventures have invested $2.4MM to locate all of the company’s business in its custom-built facility in Germantown, MD which is expected to be fully operational by 31st March 2012.Continue Reading
Date Posted: January 31, 2012
Date Posted: January 31st, 2012 Summary: Yesterday the FDA announced that Roche and Genentech had been granted approval for the targeted cancer drug, Vismodegib for the treatment of basal cell carcinoma. The approval was granted under the agency’s priority review program that provides for an expedited six-month review of drugs that may offer major advancesContinue Reading
Date Posted: December 23, 2011
Summary: A paper on a presentation by Dr Mark Seymour on the use of AMS as a frontline technique in bioanalytical detection has been published in the December 2011 issue of Bioanalysis. The paper was presented at the Reid Bioanalytical Forum in July earleir this year. The full paper can be downloaded from the FutureContinue Reading
The Team
Xceleron RSS Feed